drug · antibody
TEZSPIRE
updated 6mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 2Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 6 investigational indications.
targets
Thymic stromal lymphopoietin
all catalysts(0)
nothing on the calendar yet
Trials studying TEZSPIRE
News(9)
- Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’Windward Bio’s IPO has blown to exactly the spot the Swiss biotech had been aiming for, bringing in $225 million to fund a pair of respiratory drugs licensed from China.fiercebiotech · 6d ago
- Windward prices $175M IPO to advance China-licensed lung drugsThe Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.biopharma_dive · 6d ago
- Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from ChinaWindward Bio is sailing toward the public markets with the aim of raising over $200 million in proceeds to fund two respiratory drugs licensed from China.fiercebiotech · 10d ago
- Alcon and OpenAI make acquisitions; Tezspire's latest Phase 3 winAlcon acquires Neurotech: The Swiss eye specialist paid $550 million upfront to acquire Neurotech Pharmaceuticals and could make additional payments if certain milestones are met. Alcon gains hold…endpoints · 28d ago
- Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug dataBausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.biopharma_dive · 1mo ago
- AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPDWith a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become…fiercebiotech · 2mo ago
- AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis winEven without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.biospace · 2mo ago
- New data could widen use of AstraZeneca, Amgen immune disease drugTezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.biopharma_dive · 2mo ago
- AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitisAstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion i…biospace · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that